Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo

The New England Journal of Medicine
W BruggerL Kanz

Abstract

Autologous peripheral-blood progenitor cells can restore hematopoiesis after high-dose chemotherapy in patients with solid tumors or hematologic cancers. We investigated the ability of peripheral-blood progenitor cells generated ex vivo to restore hematopoiesis in patients with cancer who have undergone high-dose chemotherapy. Ten patients who had received high-dose chemotherapy were given transplants of autologous progenitor cells that had been generated ex vivo. We used 11 million CD34+ hematopoietic progenitor cells as the starting population for the cell growth. This number corresponds to less than 10 percent of the usual preparation of peripheral-blood CD34+ mononuclear cells used in leukapheresis. The CD34+ cells were grown in medium containing autologous plasma, recombinant human stem-cell factor, interleukin-1 beta, interleukin-3, interleukin-6, and erythropoietin. No toxic effects were observed with the infusion of the generated cells. The cells promoted a rapid and sustained hemopoietic recovery when transplanted after treatment with high-dose etoposide (1500 mg per square meter of body-surface area), ifosfamide (12 g per square meter), carboplatin (750 mg per square meter), and epirubicin (150 mg per square meter). T...Continue Reading

Citations

Apr 5, 1997·Biotechnology and Bioengineering·P W ZandstraJ M Piret
Aug 20, 1997·Biotechnology and Bioengineering·P C CollinsW M Miller
Apr 1, 1999·Biotechnology and Bioengineering·D MöbestR Henschler
Jan 1, 1997·Stem Cells·M EderA Ganser
Jan 1, 1997·Stem Cells·T J MacVittie
May 25, 2001·International Journal of Hematology·C M BollardM K Brenner
Jun 1, 1996·Medical Oncology·M HanssonP Engervall
Feb 1, 1994·Medsurg Nursing : Official Journal of the Academy of Medical-Surgical Nurses·D Wright
Nov 29, 1996·Journal of Immunological Methods·P VollmerS Rose-John
Dec 1, 1995·Blood Reviews·H E HeslopM K Brenner
Sep 1, 1996·Blood Reviews·M J Alcorn, T L Holyoake
Feb 13, 2001·Experimental Hematology·I McNiece, R Briddell
Mar 18, 2000·Experimental Hematology·D L HevehanW M Miller
Oct 2, 1998·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·S Fetscher, R Mertelsmann
May 7, 1997·Transfusion Science·A RiceJ Reiers
Apr 1, 1996·Current Opinion in Biotechnology·P C CollinsW M Miller
Sep 21, 2000·Critical Reviews in Oncology/hematology·N SabaA Keating
Jul 1, 1997·Critical Reviews in Oncology/hematology·V Rizzoli, C Carlo-Stella
Jul 25, 2003·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Jae-Lyun LeeCheolwon Suh
Aug 6, 2000·British Journal of Haematology·A L DrayerE Vellenga
Sep 13, 2001·British Journal of Haematology·K MiyamotoT Nakahata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.